- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04131530
Automatic Evaluation of Inflammation Activity in Ulcerative Colitis Using pCLE With Artificial Intelligence
October 17, 2019 updated by: Yanqing Li, Shandong University
Automatic Evaluation of Inflammation Activity in Ulcerative Colitis Using Probe-based Confocal Laser Endomicroscopy With Artificial Intelligence
Probe-based confocal laser endomicroscopy (pCLE) is an endoscopic technique that enables to evaluate the inflammation activity of ulcerative colitis with excellent correlation with histopathology.
However this requires much experience, which limits the application of pCLE.
The investigators designed a computer-aided diagnosis program using deep neural network to make diagnosis automatically in pCLE examination and contrast its performance with endoscopists.
Study Overview
Status
Unknown
Intervention / Treatment
Study Type
Observational
Enrollment (Anticipated)
60
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Shandong
-
Jinan, Shandong, China, 250012
- Recruiting
- Department of Gastroenterology, Qilu Hospital, Shandong University
-
Contact:
- Yanqing Li, PhD. MD.
- Phone Number: 053182169385
- Email: liyanqing@sdu.edu.cn
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Consecutive patients who receive the endoscopy pCLE examination and screened that fulfill the eligibility criteria at Qilu Hospital, Shandong University will be enrolled into the study
Description
Inclusion Criteria:
- aged between 18 and 80; diagnosed as UC
Exclusion Criteria:
- Patients under conditions unsuitable for performing CLE including coagulopathy , impaired renal or hepatic function, pregnancy or breastfeeding, and known allergy to fluorescein sodium; Inability to provide informed consent
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Colon mucosa observed by pCLE
pCLE is used to evaluate the inflammation activity in different parts of the colon mucosa
|
When the colon mucosa is observed using pCLE, endoscopist and AI will make a diagnosis independently.
In addition, the endoscopist can not see the diagnosis of AI.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The diagnosis efficiency of Artificial Intelligence
Time Frame: 3 months
|
The primary outcome is to test the diagnostic accuracy, sensitivity, specificity, PPV, NPV of the Artificial Intelligence for evaluation of inflammation activity of UC on pCLE examination.
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Contrast the diagnosis efficiency of Artificial Intelligence with endoscopists
Time Frame: 3 months
|
The secondary outcome is to compare the diagnosis efficiency (including diagnostic accuracy, sensitivity, specificity, PPV, NPV ) between Artificial Intelligence and endoscopists.
|
3 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
October 1, 2019
Primary Completion (Anticipated)
December 1, 2019
Study Completion (Anticipated)
December 1, 2019
Study Registration Dates
First Submitted
October 17, 2019
First Submitted That Met QC Criteria
October 17, 2019
First Posted (Actual)
October 18, 2019
Study Record Updates
Last Update Posted (Actual)
October 18, 2019
Last Update Submitted That Met QC Criteria
October 17, 2019
Last Verified
October 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2019SDU-QILU-10
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ulcerative Colitis
-
Ferring PharmaceuticalsCompletedActive Ulcerative Colitis | Remission of Ulcerative ColitisCanada
-
Palatin Technologies, IncRecruitingUlcerative Colitis | Ulcerative Colitis Flare | Ulcerative Colitis Acute | UlcerativeUnited States
-
Theravance BiopharmaCompletedUlcerative Colitis, Active Severe | Ulcerative Colitis, Active ModerateUnited States, Georgia, Moldova, Republic of, Romania
-
Rise Therapeutics LLCUniversity of Colorado, Denver; Mayo ClinicRecruitingUlcerative Colitis | Ulcerative Colitis Chronic Moderate | Ulcerative Colitis Chronic | Ulcerative Colitis Chronic MildUnited States
-
Assistance Publique - Hôpitaux de ParisMRSU 938 - Research Center of Saint AntoineNot yet recruitingPediatric Ulcerative Colitis in RemissionFrance
-
Protagonist Therapeutics, Inc.CompletedUlcerative Colitis Chronic Moderate | Ulcerative Colitis Chronic SevereUnited States, Austria, Bulgaria, Canada, Georgia, Germany, Hungary, Italy, Korea, Republic of, Poland, Russian Federation, Serbia, Ukraine
-
Theravance BiopharmaCompletedActive Mild Ulcerative Colitis, Active Moderate Ulcerative Colitis, Healthy SubjectsUnited States
-
Altheus Therapeutics, Inc.UnknownUlcerative Colitis | Left-sided Ulcerative Colitis | Distal Ulcerative ColitisUnited States
-
Groupe d'Etude Therapeutique des Affections Inflammatoires...CompletedIntensive Treatment to Reach the Target With Golimumab in ulcErative coliTis - In-TARGET (In-TARGET)ULCERATIVE COLITISFrance, Belgium
-
Xijing Hospital of Digestive DiseasesNot yet recruitingUlcerative Colitis Chronic Moderate | Ulcerative Colitis Chronic Severe | Rectal UlcerChina
Clinical Trials on The diagnosis of Artificial Intelligence and endoscopist
-
Shandong UniversityUnknownEsophageal Neoplasms | Artificial Intelligence | Confocal Laser EndomicroscopyChina
-
Shandong UniversityCompletedArtificial Intelligence | Gastric Diseases | Confocal Laser EndomicroscopyChina
-
Shandong UniversityRecruitingArtificial Intelligence | Endoscopy | Intestinal Metaplasia of Gastric MucosaChina
-
Shandong UniversityRecruitingGastric Cancer | Artificial Intelligence | Gastric Intestinal Metaplasia | PathologyChina
-
Shandong UniversityLinyi County People's Hospital,Dezhou,ChinaRecruitingArtificial Intelligence | Endoscopy | Atrophic GastritisChina
-
The First Affiliated Hospital with Nanjing Medical...The First Affiliated Hospital of Soochow UniversityRecruitingthe Application of Artificial Intelligence in the Diagnosis of Prostate CancerChina
-
Hospices Civils de LyonActive, not recruiting
-
Petz Aladar County Teaching HospitalCompletedSoftware Analysis on Polyp Histology Prediction
-
Shanghai Mental Health CenterNot yet recruitingArtificial Intelligence | Mental Illness
-
Shanghai Jiao Tong University School of MedicineCompleted